CellVec is a gene therapy Contract Development and Manufacturing Organisation (CDMO).
We specialise in research, translational development and GMP manufacturing of gene transfer vectors.
Guided by the extensive experience of our founders, Dr Lim ZiYi and Dr Lucas Chan and with the use of our lentivirus-based CellVec Vector Platform we set ourselves apart through the ability to overcome current technological bottlenecks in the upscale production of viral vectors and develop novel gene transfer technologies for advanced therapies in order to facilitate the advancement of our client’s products from bench-to-bedside for clinical applications.
CellVec is a subsidiary of TalkMed Group.
The established premier provider of medical oncology and palliative care in Asia.
A BRIEF HISTORY
CellVec was first conceived as the cell and gene therapy division of Stem Med, a joint venture between the TalkMed Group and Stemcord Pte Ltd. Stem Med’s focus lies in the development of an adult stem cell bank for advanced therapeutic use. In August 2018, CellVec was spun-off from Stem Med to further our dedication to bringing gene therapy to patients-in-need.
MILESTONES
|
March 2017
|
CellVec Advanced Therapy Division was established within Stem Med Pte Ltd, Singapore
|
|
May 2017
|
CellVec’s Research and Process Development laboratories were established
|
|
August 2017
|
Feasibility study on CellVec’s GMP facility was completed
|
|
September 2017
|
Convened consultations with Health Sciences Authority (HSA) on the facility design
|
|
December 2017 – June 2018
|
Design and construction of CellVec’s GMP facility commenced
|
|
August 2018
|
CellVec was established as a Pte Ltd
|
|
End 2018
|
Construction of CellVec’s GMP facility completed
|
|
End 2018
|
CellVec’s lentivirus-based platform established (CellVec Vector Platform)
|
|
Q1 2019
|
CellVec’s GMP facility Start Up with Performance Qualification
|
|
Q2 2019
|
CellVec’s GMP manufacturing goes online
|
